BOSTON – May 12, 2022: CureLab Veterinaryhas been notified by the European Medicines Agency (EMA) that Elenavet™, the company’s lead product, has been designated a biologic veterinary product by the Committee for Veterinary Medicinal Products (CVMP).
The CVMP plays a vital role in the authorization of veterinary medicines in the European Union (EU) and contributes to the development of veterinary medicines and medicine regulation by providing scientific advice to companies researching and developing new veterinary medicines.
The EMA informed CureLab Veterinary that its February 2022 request to classify Elenavet, intended for the treatment of breast cancer in dogs, was considered by the CVMP at its meeting of April 11-13, 2022.
According to the letter received by the company, “CVMP is of the opinion that Elenavet can be classified as a biological veterinary medical product (VMP).” According to the EMA regulations, defining a regulatory path for a VMP depends on the class of a drug.
“We are very encouraged to be given this European feedback, as it potentially allows our activities in the United States to be utilized for EU licensure as well,” said Robert Devlin, DVM, MBA, of CureLab Veterinary. “Clearly, the opportunity to license Elenavet in two major markets brings increased support for pets, wider treatment options for veterinarians, and increased revenue for our stakeholders.”
CureLab Veterinary plans to obtain regulatory approval in Europe, a market that represents enormous revenue potential for Elenavet—there are 85 million dogs and 103 million cats in Europe. According to the Veterinary Cancer Society (2017), cancer was the leading cause of death in 47 percent
Today, our four-legged family members are living longer than ever. Unfortunately, with this longer lifespan, our furry friends now are experiencing many of the same cancers and diseases due to chronic inflammation as their pet parents. CureLab Veterinary, a sister company of CureLab Oncology, is dedicated to bringing advanced therapies to treat cancer and inflammatory diseases to support better pet health and longevity. To learn more, visit curelabveterinary.com.
Tim Cox, ZingPR, firstname.lastname@example.org